Hoya (HOCPY) Stock Rating Lowered by Zacks Investment Research

Hoya (OTCMKTS:HOCPY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, September 11th.

According to Zacks, “Hoya Corporation is a specialty manufacturer of optical glass. The Company’s business activities include information technology, eye care, medical, and imaging systems. Its information technologies products include mask blanks and photomasks for semiconductor and LCD, glass memory disks, optical lenses, laser equipment and glass for electronic materials. Its eye care segment includes eyeglass lenses, contact lenses and intraocular lenses while the medical segment includes endoscopic imaging devices and hydroxyapatite. The Company’s imaging system offers digital cameras and CCTV lenses. It also offers system architecture, crystal products, surveying instruments. Hoya Corporation is based in Tokyo, Japan. “

Shares of Hoya stock traded down $0.02 during trading on Tuesday, hitting $59.92. The stock had a trading volume of 15,294 shares, compared to its average volume of 27,023. The firm has a market capitalization of $22.72 billion, a PE ratio of 25.71, a price-to-earnings-growth ratio of 2.16 and a beta of 0.84. Hoya has a 12 month low of $46.18 and a 12 month high of $62.00.

Hoya (OTCMKTS:HOCPY) last released its earnings results on Friday, August 3rd. The technology company reported $0.69 earnings per share (EPS) for the quarter. The firm had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.23 billion. Hoya had a net margin of 18.71% and a return on equity of 18.87%. Equities analysts forecast that Hoya will post 2.76 EPS for the current year.

Hoya Company Profile

HOYA Corporation engages in the life care and information technology businesses. The company offers healthcare products, including eyeglass and contact lenses; and medical products, such as medical endoscopes, laparoscopic surgical instruments, intraocular lenses, and prosthetic ceramic fillers and orthopedic implants.

See Also: NASDAQ

Get a free copy of the Zacks research report on Hoya (HOCPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hoya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoya and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply